PMID- 15355456
OWN - NLM
STAT- MEDLINE
DCOM- 20050315
LR  - 20151119
IS  - 0300-0664 (Print)
IS  - 0300-0664 (Linking)
VI  - 61
IP  - 3
DP  - 2004 Sep
TI  - Type V phosphodiesterase inhibitor treatments for erectile dysfunction increase 
      testosterone levels.
PG  - 382-6
AB  - OBJECTIVE: Lack of sexual activity due to erectile dysfunction (ED) decreases 
      testosterone (T) levels through a central effect on the hypothalamic-pituitary 
      axis. In this paper we studied the effect of different type V phosphodiesterase 
      (PDE5) inhibitor treatments for ED on the reversibility of this endocrine 
      pattern. DESIGN: Open-label, retrospective study. PATIENTS: Seventy-four 
      consecutive patients were treated on demand with sildenafil (Sild) (50 mg) and 
      tadalafil (Tad) 20 mg. MEASUREMENTS: The success in sexual intercourse was 
      recorded and total (tT) and free testosterone (fT) levels were studied before and 
      after 3 months of treatment. RESULTS: Basal level of tT and fT were at the bottom 
      of the normal range and LH levels were at the top of the high normal range. After 
      treatments, this endocrine pattern was reversed in both groups. However, the T 
      increase in Sild-treated patients was significantly lower than in those treated 
      with Tad (4.7 +/- 2.7 vs. 5.1 +/- 0.9, P < 0.001). fT levels followed a directly 
      proportional pattern, while the inverse was found when LH production was studied. 
      The intercourse rate reflected this effect: in fact, the Sild group showed a 4.9 
      +/- 2.9/month full sexual intercourse rate while in the Tad group a significantly 
      higher rate of sexual intercourse was found (6.9 +/- 4.6/month, P = 0.04). 
      However, drug consumption was comparable between the groups (Sild 4.9 +/- 2.9 vs. 
      Tad 4.4 +/- 2.8 pills/month, P = 0.72). CONCLUSIONS: As it is unlikely that the 
      two drugs have a different direct effect on the pituitary-testis axis, this 
      effect is probably due to the higher frequency of full sexual intercourse in the 
      Tad-treated group, because of the drug's longer half-life.
FAU - Carosa, Eleonora
AU  - Carosa E
AD  - Department of Experimental Medicine, University of L'Aquila, L'Aquila, Italy.
FAU - Martini, Paolo
AU  - Martini P
FAU - Brandetti, Fulvia
AU  - Brandetti F
FAU - Di Stasi, Savino M
AU  - Di Stasi SM
FAU - Lombardo, Francesco
AU  - Lombardo F
FAU - Lenzi, Andrea
AU  - Lenzi A
FAU - Jannini, Emmanuele A
AU  - Jannini EA
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Endocrinol (Oxf)
JT  - Clinical endocrinology
JID - 0346653
RN  - 0 (Carbolines)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 3XMK78S47O (Testosterone)
RN  - 742SXX0ICT (Tadalafil)
RN  - 9002-67-9 (Luteinizing Hormone)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - EC 3.1.4.- (Phosphoric Diester Hydrolases)
RN  - EC 3.1.4.35 (3',5'-Cyclic-GMP Phosphodiesterases)
RN  - EC 3.1.4.35 (Cyclic Nucleotide Phosphodiesterases, Type 5)
RN  - EC 3.1.4.35 (PDE5A protein, human)
SB  - IM
MH  - 3',5'-Cyclic-GMP Phosphodiesterases
MH  - Adult
MH  - Aged
MH  - Carbolines/*therapeutic use
MH  - Cyclic Nucleotide Phosphodiesterases, Type 5
MH  - Erectile Dysfunction/*blood/*drug therapy
MH  - Humans
MH  - Luteinizing Hormone/blood
MH  - Male
MH  - Middle Aged
MH  - Phosphodiesterase Inhibitors/*therapeutic use
MH  - *Phosphoric Diester Hydrolases
MH  - Piperazines/*therapeutic use
MH  - Purines
MH  - Retrospective Studies
MH  - Sildenafil Citrate
MH  - Sulfones
MH  - Tadalafil
MH  - Testosterone/*blood
EDAT- 2004/09/10 05:00
MHDA- 2005/03/16 09:00
CRDT- 2004/09/10 05:00
PHST- 2004/09/10 05:00 [pubmed]
PHST- 2005/03/16 09:00 [medline]
PHST- 2004/09/10 05:00 [entrez]
AID - CEN2108 [pii]
AID - 10.1111/j.1365-2265.2004.02108.x [doi]
PST - ppublish
SO  - Clin Endocrinol (Oxf). 2004 Sep;61(3):382-6. doi: 
      10.1111/j.1365-2265.2004.02108.x.